Sertraline in the treatment of panic disorder: A double-blind multicenter trial

American Journal of Psychiatry

Volumn 155, Issue 9, 1998, Pages 1189-1195

  Pohl, Robert B ^b   Wolkow, Robert M ^a   Clary, Cathryn M ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANIC; PRIORITY JOURNAL; QUALITY OF LIFE; REPRODUCTIVE TOXICITY; XEROSTOMIA;

EID: 0031683510     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.9.1189     Document Type: Article

References (30)

1. Roy-Byrne P, Wingerson D, Cowley D, Dager S: Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am 1993; 16:719-735
2. Pohl R, Yeragani VK, Balon R, Lycaki H: The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988; 49:100-104
3. Noyes R Jr, Garvey MJ, Cook BL, Samuelson L: Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50:163-169
4. Schweizer E, Rickels K, Weiss S, Zavodnick S: Maintenance drug treatment of panic disorder, I: results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993; 50:51-60
5. Jobson KO, Davidson JR, Lydiard RB, McCann UD, Pollack MH, Rosenbaum JF: Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull 1995; 31: 483-485
6. den Boer JA, Westenberg HG, De Leeuw AS, van Vliet IM: Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. Int Clin Psychopharmacol 1995; 9(suppl 4): 47-52
7. Hoehn-Saric R, McLeod DR, Hipsley PA: Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13: 321-326
8. Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50:44-50
9. Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, Thibaudeau C, Raine D: A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996; 32:135-141
10. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167:374-379
11. Lecrubier Y, Bakker A, Dunbar G, Judge R: A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder: Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95:145-152
12. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J: Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51(suppl B):18-27
13. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52:289-295
14. Gupta MA, Gupta AK: Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants? Cutis 1995; 56:53-54
15. Papp LA, Weiss JR, Greenberg HE, Rifkin A, Scharf SM, Gorman JM, Klein DF: Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders (letter). Am J Psychiatry 1995; 152:1531
16. Spitzer RL, Williams JBW, Gibbon M: Structured Clinical Interview for DSM-III-R - Patient Version (SCID-P). New York, New York State Psychiatric Institute, Biometrics Research, 1989
17. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
18. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
19. Grebb JA: Psychiatric rating scales, in Comprehensive Textbook of Psychiatry, 5th ed, vol 1. Edited by Kaplan HI, Sadock BJ. Baltimore, Williams & Wilkins, 1989, pp 544-545
20. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
21. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29:321-326
22. Shear K, Sholomskas D, Cloitre M: MC-PAS: The Multicenter-Panic Anxiety Scale. Pittsburgh, University of Pittsburgh School of Medicine, Department of Psychiatry, 1992
23. Shear MK, Maser JD: Standardized assessment for panic disorder research: a conference report. Arch Gen Psychiatry 1994; 51:346-354
24. Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45:413-422
25. Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R: A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992; 12:96-103
26. Schweizer E, Patterson W, Rickels K, Rosenthal M: Doubleblind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993; 150:1210-1215
27. Hirschfeld RMA: Placebo response in the treatment of panic disorder. Bull Menninger Clin 1996; 60(suppl A):A76-A86
28. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF: Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993; 13:257-263
29. Keller MB, Hanks DL: Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:551-570
30. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF: An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7:329-332